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Summary 
Pseudomonas aeruginosa lung infections are a leading cause of morbidity and mortality in cystic 
fibrosis (CF) patients (1, 2). Our laboratory has studied a class of small molecules produced by P. 
aeruginosa known as phenazines, including pyocyanin and its biogenic precursor phenazine-1-carboxylic 
acid (PCA). As phenazines are known virulence factors (3), we and others have explored the possibility of 
using phenazine concentrations as a marker for disease progression (4-6). Previously, we reported that 
sputum concentrations of pyocyanin and PCA negatively correlate with lung function in cystic fibrosis 
patients (6). Our study used high performance liquid chromatography (HPLC) to quantify phenazines by 
UV–vis absorbance after extraction from lung sputum. Since our initial study, methods for metabolite 
analysis have advanced considerably, aided in large part by usage of mass spectrometry (LC-MS) and 
tandem mass spectrometry (LC-MS/MS). Because a more recent study employing LC-MS/MS revealed a 
surprising decoupling of P. aeruginosa metabolites in sputum and the detection of P. aeruginosa through 
culturing or microbiome profiles (4), we decided to check whether we could reproduce our previous 
findings by analyzing sputum samples from a different patient cohort with a new LC-MS instrument in our 
laboratory. Our new samples were provided by the Mountain West CF Consortium Sputum Biomarker 
study (7). In the course of performing our new analyses, comparison of our old HPLC data to our new LC-
MS data led us to realize that the peak previously assigned to PCA instead originates from heme, and the 
peak assigned to pyocyanin originates from an as-yet unknown compound. This correction only affects the 
measurements of phenazines in sputum, and we are confident in the phenazine measurements from isolated 
cultures and the 16S rRNA gene sequencing data from that study (6). Here we outline the basis for our 
correction and present additional data showing that heme concentration negatively correlates with lung 
function in cystic fibrosis patients. 
Results 
Identification of heme in sputum 
Motivated by a recent LC-MS/MS study which reported phenazines in only a fraction of samples 
with P. aeruginosa (4), we sought to determine whether we could repeat our previously reported correlation 
between phenazines and disease progression (measured by FEV1%). We obtained fresh sputum samples 
from the Mountain West CF Consortium (MWCFC) sputum biomarker study and analyzed 71 sputum 
supernatants using HPLC coupled to UV–vis detection and a single quadrupole mass spectrometer (Waters 
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Acquity QDa). Patients with confirmed CF enrolled in the MWCFC study were randomly selected from all 
sputum producers followed by the participating centers and enrolled during clinical stability. Patients had 
a mean age of 28 years (SD=12), FEV1% of 70% (SD = 22), weight-for-age z-score of −0.17 (SD=0.98) at 
the time of enrollment. Patients had a history of 1.7 pulmonary exacerbations in the year prior to enrollment 
(SD=1.7), diabetes in 22%, pancreatic insufficiency in 92.1% and 5-year survival predictions (8) ranging 
from 9.4% to >99.99% (median 94%). P. aeruginosa was recovered from 61% of cultures from enrollment 
and 74% of cultures obtained during the year of enrollment from the MWCFC patients. There were no 
significant differences between the characteristics of the MWCFC study group and the same characteristics 
of patients six years of age and able to produce sputum found in the 2014 CF Foundation Patient Registry 
(7). 
To our surprise, and in contrast to our prior study, we were unable to detect the phenazines 
pyocyanin, PCA, phenazine-1-carboxamide, or phenazine-1-hydroxide in any of the samples to within our 
detection limit (approximately 0.1 µM) in either the UV–vis or mass channels. Instead, we observed a late-
eluting compound in all 71 samples which had an absorbance spectrum that overlaps with the phenazine 
spectrum but is distinguished by a maximum at 398 nm. This compound produced positive ions at an m/z 
of 616.2, further distinguishing it from any known phenazine, and it was present even in patients who did 
not test positive for P. aeruginosa. We noted a striking similarity between the UV–vis spectrum of this 
compound with published spectra for the porphyrin ring of heme-like compounds (9). We therefore 
wondered whether this peak represented a compound related to heme, and whether we might have mis-
assigned it previously in sputum samples, which are more chemically complex than bacteriological media. 
To further interrogate the peak, we transferred our method to an instrument coupled to a high-
resolution quadrupole time-of-flight mass spectrometer (Waters Xevo). Again we consistently observed a 
UV–vis chromatographic peak at 398 nm (Figure 1A). Consistent with its identity as a heme, this peak had 
a retention time identical to that of a hemin standard (Figure 1A). Both the sputum samples and the hemin 
standard gave an equivalent peak in the extracted ion chromatogram for an m/z of 616.1773 ± 0.01 (Figure 
1A), the m/z expected for hemin having lost its associated chloride ion to produce ferriprotoporphyrin IX. 
We note that the hemin standard was dissolved in base, a condition known to replace the chloride ion with 
hydroxide (10) which is subsequently removed in the acidic conditions of our chromatography, therefore 
explaining the origin of ferriprotoporphyrin IX from our hemin standard. In the positive ion channel (Figure 
1B), sputum and hemin produced equivalent signals that were indistinguishable from the expected mass of 
ferriprotoporphyrin IX to within the resolution of the instrument (∆ppm = 0.97 and −1.6, respectively). 
Similarly, in the negative channel (Figure 1C), both sputum and hemin produced ions consistent with the 
formic acid adduct of ferriprotoporphyrin IX (∆ppm = −0.45 and 0.45, respectively), an additive used in 
our separation method. Application of collision energy produced equivalent fragmentation patterns in the 
negative ion mode (Figure 1C) with the major daughter ion appearing around 570.1718, consistent with 
two decarboxylations or a single decarboxylation and loss of formic acid. The sputum peak and the hemin 
standard also produced indistinguishable UV−vis spectra (Figure 1D) which closely matched previous 
reports for heme (9). Based on identical retention times, mass and UV–vis spectra, and mass fragmentation 
patterns, we assign this peak to ferriprotoporphyrin IX, also known as heme B (Figure 1E). 
Re-analysis of the original data 
Though the MWCFC cohort differed in inclusion criteria from that used in our prior Children’s 
Hospital Boston (CHB) sputum study (i.e. a positive diagnosis of CF based on genotyping or sweat test and 
positive P. aeruginosa culture), we were nevertheless surprised that we were unable to detect phenazines 
in the MWCFC samples with our newer instrument. At the time of our previous analysis, we were using an 
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older HPLC instrument equipped with UV–vis detection but not mass detection, thus we became concerned 
that we may have mis-identified other compounds as phenazines using this older instrument and decided to 
revisit our old raw data. In the CHB study, we employed a standard protocol, used by our group and others 
for routine phenazine analysis in bacteriological cultures, which detects phenazines by their retention times 
in UV–vis chromatograms (387 nm for pyocyanin and 364 nm for PCA). We used this method to quantify 
phenazine production from 779 clinical isolates from CF sputum from 47 CHB patients (6). Re-examination 
of the raw data from these samples confirmed appropriate phenazine assignment. To quantify phenazines 
in CF sputum, we co-injected pyocyanin or PCA into sputum from which we could not culture P. 
aeruginosa (a major source of phenazines in cystic fibrosis patients) and ran standard curves. In these 
control co-injection samples, we observed distinct HPLC peaks at 387 nm and 364, as would be expected 
for pyocyanin or PCA, respectively. Accordingly, we used absorption at these wavelengths to quantify 
phenazines in all sputum samples. With the benefit of our new awareness that heme B shares retention and 
absorption characteristics with PCA, we revisited the complete spectral data for each peak from the raw 
data on our old HPLC, suspecting that we might have unwittingly mis-assigned phenazines to other 
compounds in sputum. Indeed, analysis of the full UV–vis spectra revealed that the sputum peak we had 
tracked at 364 nm and assigned to PCA had an absorbance maximum at 398 nm (Figure 2A), suggesting it 
is unlikely to be PCA despite similar retention times and overlapping absorbance spectra. Instead, this 
peak’s absorbance spectrum closely matched the spectrum of ferriprotoporphyrin IX identified in our new 
study (Figure 1D), suggesting we had mis-assigned the heme peak as PCA. Similarly, the sputum peak 
previously assigned to pyocyanin has an absorbance maximum around 360 nm (Figure 2B) instead of 387 
nm, suggesting that pyocyanin is not the major component of this peak. The early-eluting portion of the 
chromatogram that contains pyocyanin is crowded by multiple overlapping peaks with similar spectra, and 
so we have been unable to characterize it further. 
Despite our best efforts to perform appropriate controls, including co-injections, the UV–vis spectra 
reveal that the peaks for pyocyanin and PCA were incorrectly assigned in the original CHB study. This 
error stemmed from the co-elution of phenazines with sputum compounds that have similar absorbance 
spectra and the lack of a MS system on the older HPLC instrument. In addition, this instrument was 
equipped with preparative-scale pumps which led to greater retention time variability between HPLC 
samples (up to ±1 minute for PCA) compared to analytical instruments, further masking the incorrect 
assignment. While we cannot rule out the possibility that phenazines were present in our old samples, the 
distinct UV–vis absorbance spectra indicate that phenazines were not the major component of the assigned 
peaks, and so our original report overestimated the phenazine concentration in CF sputum samples. 
Heme concentrations correlate negatively with lung function 
As the re-analysis suggests, the interpretation of our original HPLC data was confounded by co-
eluting compounds that are present in sputum. The similarity between the peak we previously analyzed as 
PCA and what we have now identified as ferriprotoporphyrin IX (Figure 1D) suggests that, instead of a 
correlation between phenazines and FEV1 %, the original study measured a correlation between heme and 
FEV1%. To evaluate this possibility, we quantified the concentration of ferriprotoporphyrin IX in our 
MWCFC samples from our new dataset. A plot of heme concentration versus FEV1% reveals a statistically 
significant (Spearman’s ρ = −0.47, p < 0.001) correlation between sputum heme levels and FEV1% (Figure 
3). Three of the samples contained substantially more heme than the others, and this correlation held even 
when the outliers with >10 µM heme were excluded from the analysis (ρ = −0.41, p < 0.001) because the 
Spearman rank correlation is independent of the magnitude of the variables. Although the concentration of 
ferriprotoporphyrin IX in the original samples is unknown, it is likely that the original PCA concentration 
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data instead represents heme concentration with an unknown conversion factor, and so both studies have 
independently confirmed a correlation between the heme signal in HPLC analysis and lung function in 
cystic fibrosis patients. 
Discussion 
Several independent analyses have detected phenazines in sputum from cystic fibrosis patients (4, 
5). Our new data collection effort and the correction reported here to our previous results (6) was partially 
motivated by a more recent report of detectable phenazine concentrations in only 3 of 27 patients (4). 
Interestingly, extensive isolation of several hundred clinical P. aeruginosa strains in our lab has verified 
that phenazine production is a nearly universal capability of P. aeruginosa strains that inhabit cystic fibrosis 
patients, a result that is still valid from our original study (6). All phenazine analyses in the original paper 
that were performed in bacteriological growth medium were accurate. We therefore find it interesting that 
phenazines and other P. aeruginosa metabolites are detected only sporadically in sputum samples, often 
from patients that are culture-negative for P. aeruginosa (4). Together these findings are suggestive of 
significant macro- and micro-scale heterogeneity within cystic fibrosis lungs. Consistent with regional 
heterogeneity, P. aeruginosa strains within different regions are known to undergo independent evolution 
with minimal cross-colonization (11). It is difficult to verify that independent samples originate from the 
same region of the lung, and so heterogeneity between sputum samples may account for differences 
between metabolite and microbial analyses within the same patient. Furthermore, sputum samples are 
extremely viscous and poorly mixed, leading to high spatial heterogeneity within individual samples (12). 
Sputum viscosity originates from extracellular polymers including DNA (13), and because pyocyanin and 
other phenazines are known DNA intercalators (14), it is likely that cells within the sputum matrix 
encounter a micro-scale phenazine concentration that is considerably higher than that determined by bulk 
measurements. We anticipate that new methods to image metabolites at large and small spatial scales will 
provide insights into the cystic fibrosis lung environment and clarify the role of pathogen-derived 
metabolites in disease progression. Although it remains possible that phenazine concentration negatively 
correlates with lung function, our original study overestimated the total phenazine concentration and the 
true concentrations were likely below our limit of detection. 
The form of heme we measured in this study, ferriprotoporphyrin IX or heme B, is the most 
abundant heme found in humans and the oxygen-carrying component of hemoglobin in red blood cells. 
Given that the majority of components in lung sputum are host-derived (4), the heme likely originated from 
blood rather than from microbial sources. Consistent with this assumption, hemoptysis, or coughing up 
blood, is observed in up to 60% of cystic fibrosis patients (15-17). While minor blood streaking in sputum 
does not usually prompt treatment, massive hemoptysis is a marker of pulmonary exacerbations and 
correlates with impaired lung function and mortality in adults (15, 16), and so the correlation between heme 
and lung function decline may identify heme as a potentially useful biomarker of clinical disease in CF.  
Previously we also reported a correlation between sputum iron and lung function decline (18). This 
correlation arose from the abundance of Fe(II) which predominated, rather than from Fe(III) (18). We also 
reported a correlation between Fe(II) and what we believed was PCA (18), which we now recognize was 
heme. As heme is a major carrier of iron, this correlation suggests blood-derived heme may be a significant 
source of sputum iron. In the context of lung infections, iron is an important nutritional regulator of 
pathogenicity and biofilm formation in bacteria, including P. aeruginosa (19), and pathogenic bacteria can 
extract iron from heme (9). Given that iron chelation is now being explored as a potential therapy for lung 
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infections (20), there is a need to better understand the sources of sputum iron and its influx rate, of which 
our results suggest host-derived heme could be a significant contributing factor. 
The prognosis for cystic fibrosis patients has improved remarkably in recent decades, owing not 
only to advances in treatments but also in diagnostics and preventative care (21). While the role of pathogen-
derived metabolites in disease state is still uncertain, host-derived factors are clearly abundant (4) and may 
provide new markers to guide treatment. The prevalence of heme in every sputum sample we measured, 
and the simplicity of its detection by HPLC owing to its characteristic 398 nm absorbance peak, suggest it 
can be a useful diagnostic component for monitoring cystic fibrosis disease progression. Additional 
research may uncover a causative link between sputum heme and lung disease through the interplay 
between iron and pathogenic microbes. 
Materials and Methods 
HPLC method from the original study 
The original study used a Beckman Gold HPLC equipped with preparative-scale pumps on a model 
126P solvent module. The separation used a Waters Symmetry C18 column with dimensions 4.6 mm × 250 
mm and a particle size of 5 µm. The injection volume was 100 µl, supplied via a model 508 autosampler, 
and the flow rate was 1.0 mL/min. Solvent A was water with 0.1% trifluoroacetic acid (TFA) and Solvent 
B was acetonitrile with 0.1% TFA. Compounds were eluted using a linear gradient of 15% B from 0 to 2 
minutes, 15% to 83% B from 2 to 22 minutes, and 0% B from 22 to 30 minutes. UV–vis data were collected 
from 200 to 600 nm using a model 168 photodiode array detector. 
Sample preparation 
Sputum samples were obtained after informed consent from patients with confirmed CF aged 6 and 
older able to expectorate sputum during clinical stability. The study protocol was reviewed and approved 
at each of the 9 participating centers in the Mountain West CF Consortium (MWCFC). Patients were 
randomly selected from the MWCFC Centers in order to enroll a representative sample of all US patients 
with CF. Samples were processed within 4 hours of expectoration by dilution 1:1 with Hanks buffered 
saline solution (Sigma, St Louis, MO), vigorous vortex mixing for 1 minute followed by centrifugation at 
2,800 g and 4 °C for 20 minutes to obtain lipid and aqueous fractions and pellets. For this study, we used 
aqueous fractions that were mixed 1:1 with protease inhibitor cocktail (Sigma). Fractions were frozen and 
stored at −80 °C until use. The samples were thawed at room temperature and centrifuged at 13,000 g for 
15 minutes. The supernatant was transferred to a Waters Total Recovery Vial and injected directly into the 
HPLC without further processing. Hemin was purchased from Sigma-Aldrich and was dissolved to a stock 
concentration of 10 mM using 100 mM aqueous ammonia. A standard curve from 0.01 to 100 µM was 
created by diluting the stock solution into water. 
Spirometry 
Clinical data including spirometry data were collected at the same time as sputum samples. The 
forced expiratory volume in 1 second (FEV1) was measured according to American Thoracic Society 
standards (22).  FEV1 was normalized to percent predicted FEV1 (FEV1%) for age, sex, height, race and 
ethnicity using NHANES III equations (23) as was done clinically at all participating centers at the time of 
study enrollment. 
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High resolution LC-MS 
 HPLC separations for high resolution mass spectrometry were performed on a Waters Acquity I-
Class UPLC connected to a Waters Acquity PDA detector and a Waters Xevo G2-XS quadrupole time-of-
flight mass spectrometer. The sample chamber was maintained at 4 °C. The separation used a Waters 
XBridge BEH C18 XP column with dimensions 3.0 × 100 mm and a particle size of 2.5 µm. The column 
was equipped with a VanGuard guard column comprising the same resin. The injection volume was 5 µl 
and the flow rate was 0.5 mL/min. The column was maintained at 40 °C. Solvent A was water with 0.1% 
formic acid and solvent B was acetonitrile with 0.1% formic acid. Compounds were eluted using a linear 
gradient of 0% to 90% from 0 to 24 minutes, 90% B from 24 to 25 minutes, and 0% B from 25 to 35 
minutes. Mass scans from 150 to 1000 Da were collected in separate chromatographic runs for positive and 
negative ionization modes with a scan time of 0.3 s. For both modes, the mass spectrometry parameters 
were: capillary voltage, 1.5 kV; sampling cone, 30 V; source offset, 80 V; source, 120 °C; desolvation, 550 
°C; cone gas, 50 L/h; desolvation gas, 800 L/h. The analyser mode was set to resolution and the dynamic 
range was set to normal. In the negative ion mode, fragmentation data were collected in a second data 
channel using a collision-ramp energy of 10 to 14 eV. A solution of 20 pg/μL leucine enkephalin was used 
as the LockSpray solution with a flow rate of 20 μl/min. The instrument was controlled using the software 
MassLynx. 
Routine LC-MS for ferriprotoporphyrin IX quantification 
For routine analysis, HPLC separations were performed on a Waters Alliance HPLC connected to 
a Waters 2998 PDA detector and a Waters Acquity QDa single quadrupole mass spectrometer. The sample 
chamber was maintained at 10 °C. Separations were performed the same as for the high-resolution method, 
except that the gradient included a constant 2% methanol supplied via solvent C, which was found to greatly 
improve the reproducibility of pyocyanin measurements. Mass scans were collected simultaneously from 
100 to 900 Da in the positive mode and 100 to 600 Da in the negative mode. In addition, a selected ion 
recording channel was collected in the positive mode for 211.09, 224.08, and 225.07 Da, the masses 
expected for pyocyanin, phenazine-1-carboxamide, phenazine-1-carboxylic acid, respectively. The probe 
temperature was 600 °C and the capillary voltage was 0.8 kV. UV–vis data were collected from 200 to 800 
nm at 20 Hz with a resolution of 1.2 nm. The instrument was controlled using the software Empower. Peaks 
representing ferriprotoporphyrin IX were integrated using the Apex Track algorithm within Empower and 
compared against a linear calibration curve of samples derived from hemin. The measured concentrations 
were multiplied four-fold to account for the dilution that occurred during sample processing. 
Data analysis and statistics 
To ensure uniformity, data from the three instruments were exported and compared together within 
a series of Python scripts. Plots were generated using the Matplotlib package and labeled with Adobe 
Illustrator. The Spearman correlation coefficient was calculated using the spearmanr function in the SciPy 
package.  
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Figure 1. Identification of heme in sputum samples by comparing sputum (black) to a hemin standard 
(green). (A) UV–vis chromatogram (top) and extracted ion chromatogram (616.1773 ± 0.01 Da) from the 
positive mass channel (bottom) demonstrating identical retention times. (B) The associated positive ions 
detected from the peak shown in A, comparing the sputum peak (top) to the hemin standard (bottom). (C) 
The associated negative ions detected from the peak shown in B, comparing the sputum peak (top) to the 
hemin standard (bottom). A collision-energy ramp of 10 to 14 eV was applied to generate a fragmentation 
pattern. (D) Comparison of the UV–vis spectra for the peaks in A (black and green) compared to the same 
peak identified in our prior study (gray, dashed). For clarity, the spectra are normalized to their maximum 
value. (E) The chemical structure assigned to the peak in A, ferriprotoporphyrin IX. 
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Figure 2. Re-analysis of the HPLC peaks previously assigned as phenazines from the original data collected 
on an older HPLC. UV–vis chromatograms are shown on the left, and the full UV–vis spectra of the peaks 
indicated with an arrow are shown on the right. Where indicated on the y-axis, the data have been 
normalized to bring the data into the same scale for clarity. (A) Analysis of the PCA peak, comparing a 
pure PCA standard (chromatogram at 364 nm, orange) to a sputum sample (chromatogram at 398 nm, 
black). (B) Analysis of the pyocyanin peak, comparing pyocyanin in P. aeruginosa-free sputum (blue) to a 
P. aeruginosa-positive sputum sample (black) (both chromatograms at 387 nm). 
 
 
Figure 3. Correlation between ferriprotoporphyrin IX concentration and disease status as measured by 
percent predicted FEV1 (Spearman’s ρ = −0.47, p = 3.6 × 10−5). Each data point represents a single sputum 
sample from a unique patient. The dashed line illustrates a linear regression through the data. 
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